The PKA L205R hotspot mutation has been implicated in Cushing's syndrome through hyperactive gain-of-function PKA signaling; however, its influence on substrate specificity has not been investigated. Here, we employ the Proteomic Peptide Library (ProPeL) approach to create high-resolution models for PKA WT and PKA L205R substrate specificity. We reveal that the L205R mutation reduces canonical hydrophobic preference at the substrate P + 1 position, and increases acidic preference in downstream positions. Using these models, we designed peptide substrates that exhibit altered selectivity for specific PKA variants, and demonstrate the feasibility of selective PKA L205R loss-of-function signaling. Through these results, we suggest that substrate rewiring may contribute to Cushing's syndrome disease etiology, and introduce a powerful new paradigm for investigating mutation-induced kinase substrate rewiring in human disease.
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Keywords: Cushing's syndrome; protein kinase A; substrate specificity Cushing's syndrome is defined by a collection of signs and symptoms that result from prolonged hypercortisolism (due to excessive secretion of adrenocorticotropin hormone, or adrenocortical adenomas), with patients commonly presenting with central obesity, metabolic anomalies, and hypertension [1] . At a biochemical level, cAMP-dependent protein kinase A (PKA) has been implicated in Cushing's syndrome through several different lines of evidence, and PKA mutations have been identified in almost 40% of cortisol-secreting adenomas [2] . Like other protein kinases, PKA derives substrate specificity through temporal and spatial colocalization, scaffolding, and docking interactions. Kinase specificity is also determined by interactions with specific patterns of amino acids surrounding the phosphoacceptor, which is referred to as the 'kinase specificity motif' [3] . Recently, several groups genetically identified the hotspot mutation PKA L205R in patients diagnosed with Cushing's syndrome [4] [5] [6] [7] . In PKA WT residue L205 (together with residues L198 and P202) is situated in the so-called P + 1 loop, where P + n denotes the nth residue toward the C terminus of the phosphoacceptor (P-site) and P À n denotes the nth residue toward the N terminus. The P + 1 loop contributes to the PKA WT specificity motif by creating a hydrophobic pocket that favors substrates with a P + 1 hydrophobic residue [8, 9] .
Residue L205 is highly conserved in PKA homologs from humans to invertebrates, and also plays an important role in stabilizing the hydrophobic interaction with I98 in the regulatory subunit RIa pseudosubstrate sequence RRGAI (and the homologous positions in regulatory subunits RIb, RIIa, and RIIb [10] ). The role of L205 in forming the P + 1 loop and an observed increase in cAMP signaling associated with the PKA L205R mutant has led to the prevailing hypothesis that mutation from leucine to arginine disrupts the interface with regulatory subunits, resulting in a constitutively active PKA enzyme [11] .
Recently, kinase missense mutations identified from cancer patients were shown to modulate not only catalytic activity but also in some cases to alter substrate specificity [12] . Until now, there has been no investigation into the effect of the L205R mutation on PKA substrate specificity. The structures of PKA WT and PKA L205R in complex with the naturally occurring inhibitor peptide PKI (containing the pseudosubstrate sequence RRNAI) reveal a distinct reorientation of the P + 1 isoleucine in PKI when in complex with PKA L205R , with no other apparent changes in kinase substrate binding (Figs 1A and S1, [13] ). This change in binding is likely to accommodate the loss of the P + 1 loop hydrophobic pocket in the mutant, due to introduction of hydrophilic character and steric clash with the bulky arginine side chain. Based on these structural data, we hypothesized that PKA L205R would exhibit a reduced preference for substrates with a hydrophobic residue in the P + 1 position, while maintaining canonical upstream basophilic interactions.
Materials and methods

Plasmids, strains, and in vivo proteome phosphorylation
A plasmid containing the full-length coding sequences for the human PRKACA gene in the pDNR-Dual vector was purchased from the Harvard PlasmID Repository (Boston, MA, USA). Full-length PKA was cloned into the pET45b vector (Novagen, EMD Millipore, Darmstadt, Germany) by traditional restriction site PCR cloning. The PKA L205R mutation was created according to the Stratagene QuickChange II protocol. PKA constructs were transformed into the Escherichia coli Rosetta2 strain (Novagen, EMD Millipore) and expressed by IPTG induction. PKA expression was optimal when induced at mid-log with 0.5 mM IPTG and incubated overnight at 22°C with shaking at 250 rpm. Cells were harvested by centrifugation at 6000 g and 4°C for 10 min, and stored at À80°C.
Lysis and analysis of in vivo phosphorylation
Cell lysate was prepared as described previously [14, 15] with minor modifications. Cells were lysed by sonication with a Fisher Sonic Dismembrator F60 at 15% power using 15-to 20-s pulses, with 1-min rest on ice between pulses, until lysate was clear. Crude lysate was clarified by centrifugation at 20 000 g and 4°C for 30 min. Protein concentrations were determined by Bichinchoninic Acid (BCA) Assay (Pierce Biotechnology, Rockford, IL, USA), phosphorylation level was evaluated by SDS/PAGE with Pro-Q Diamond Phosphoprotein stain (Life Technologies, Carlsbad, CA, USA), and total protein was evaluated by GelCode Blue coomassie staining (Life Technologies).
Western blotting
Western blotting for PKA used primary rabbit antibody for the human catalytic subunit a (PKAa cat (C-20): sc-903, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1 : 1000 dilution, and IRDye 680RD Donkey anti-Rabbit IgG secondary antibody (LI-COR Biosciences, Lincoln, NE, USA) at 1 : 5000 dilution.
In-solution tryptic digestion
Samples were reduced, alkylated, digested with trypsin (Promega, Madison, WI, USA) at a 1 : 100 enzyme : substrate ratio, and desalted as previously described in Vill en and Gygi, steps 2-17 [14] .
TiO 2 bead phosphopeptide enrichment
Phosphopeptide enrichment using bulk TiO 2 beads (Titansphere 5 lm, GL Sciences Inc USA, Rolling Hills Estates, CA, USA) was modified from Kettenbach and Gerber [16] . Beads were conditioned in bulk using binding buffer (50% ACN, 2 M lactic acid), with beads added at a 4 : 1 ratio to peptides (peptide concentration estimated by NanoDrop A280 absorbance), and brought to a final peptide concentration of 1 which allowed for differential serine, threonine, and tyrosine phosphate modifications (+79.966331), a differential methionine oxidation modification (15.9949146221) and a constant cysteine modification of +57.02146374. The deltaXCORR (the difference between the first and second hits to the databases) was set to be ≥0.08. To minimize false positives, for each of the two classes of peptide charges z = +2 and z ≥ +3, XCORR thresholds were chosen to accept peptides in such a manner that 1% of them were hits from the decoy database, resulting in an expected false discovery rate (FDR) of 2%.
Phosphopeptide list filtering
Prior to motif analysis, a master negative control list was generated by pooling phosphopeptides previously identified in negative control experiments [15] , previously identified endogenous E. coli phosphorylation sites [17, 18] , and phosphorylation sites identified in empty vector and kinase dead negative control experiments. Phosphorylation sites on this master negative control list were removed from each PKA variant dataset to generate a final list of kinase-specific phosphorylation sites. Peptide lists from all runs were merged within each kinase variant, and redundant peptides were removed prior to motif analysis.
pLogo generation
To generate graphical motifs, known as pLogos, we used the online tool at http://plogo.uconn.edu, previously described in detail [19] . See Supporting Information for a more detailed explanation, and instructions for recreating pLogos with our provided data.
Structural modeling
All structural modeling was visualized using PyMol for Mac, and using the following structures retrieved from the RCSB Protein Data Bank: PKA WT -PDB Model 4WB5, and PKA L205R -PDB Model 4WB6 [13] .
Recombinant kinase purification PKA WT and PKA L205R were expressed as described above. P]ATP, and 1 lg of each kinase for 30 min at 30°C with slight agitation. Membranes were washed with 15 mL 1 M NaCl for 5 min, for a total of five washes, followed by three water washes. Membranes were then washed with 15 mL 5% phosphoric acid for 15 min, for a total of three washes, followed by three water washes. Membranes were air dried, and exposed to film for 3 days. Phosphorylation was analyzed by densitometry using Gilles Carpentier's Dot-Blot-Analyzer macro for ImageJ (written by Gilles Carpentier, 2008, and available at http://image.bio.methods.free.fr/dotblot.html). See Table S3 for raw data, and normalization protocol.
Results
Human PKA
WT and PKA L205R are active when expressed in Escherichia coli
In order to accurately determine specificity motifs for both PKA WT and PKA L205R , we used the Proteomic Peptide Library (ProPeL) method [15] because it allowed us to determine high-fidelity motifs for individual kinase clones expressed in isolation (i.e., in the absence of potentially confounding eukaryotic kinases). Using this approach (Fig. 1B) , first a heterologous kinase of interest is expressed in E. coli. Upon expression, the kinase phosphorylates bacterial proteins consistent with its intrinsic kinase specificity motif. After cell lysis and proteolysis, the resulting E. coli phosphopeptides are identified by tandem mass spectrometry. This can provide hundreds to thousands of kinase-specific phosphopeptides from which a high--resolution motif model is generated, and easily visualized using the pLogo graphical representation [19] .
As per the ProPeL method, we expressed the fulllength human catalytic subunit for either PKA WT or PKA L205R in the Rosetta2 E. coli strain, noting robust expression as evaluated by western blot (Fig. S2A) . Using the in-gel phosphoprotein stain Pro-Q Diamond [21] , we observed that both PKA variants exhibit strong autophosphorylation and efficiently phosphorylate E. coli proteins throughout the gel (and thus across the proteome) compared to the empty vector control (Fig. S2B,C) . Lysate from cells expressing either PKA WT or PKA L205R was digested, enriched, and subjected to phosphopeptide identification by tandem mass spectrometry. After removing endogenous E. coli phosphorylation sites, we obtained 1404 unique phosphorylation sites (1087 pSer and 317 pThr) for PKA WT , and 585 unique phosphorylation sites for PKA L205R (445 pSer and 140 pThr, see Table S1 ), consistent with the observed discrepancy between PKA WT and PKA L205R in vivo activity (Fig. S2B,C) .
PKA L205R exhibits altered substrate specificity PKA WT has a well-established specificity motif that consists of upstream basic residues (particularly at the P À 2 and P À 3 positions) and a significant enrichment for the hydrophobic (/) residues [I/L/M/V/F] at P + 1. This motif can be simplified to the consensus sequence [R/K][R/K]xS/ [9, 22] . While the PKA WT pLogo generated from our dataset faithfully recapitulates this known motif ( Fig. 2A) , the PKA L205R pLogo reveals a striking loss of hydrophobic preference (with the exception of leucine) at the P + 1 position (Fig. 2B) . In addition, we observe a strong [I/V] hydrophobic grouping at P + 2 position in the PKA WT motif, which is replaced by the acidic [D/E] grouping at this position in the PKA L205R motif. This shift toward an increased enrichment for downstream acidic residues in the motif may be due to an electrostatic interaction with a positively charged R205 guanidinium group in the mutant kinase. Conversely, we note that the canonical basophilic preference at substrate positions P À 2 and P À 3 by PKA WT was unaltered for PKA L205R , which is consistent with conserved interactions with PKI in the mutant crystal structure (Fig. S1 ). PKA L205R motifs for substrates that contain threonine P-sites are largely similar to the serine motifs, although there appears to be an even greater shift away from hydrophobic P + 1 preference and a less pronounced increase in acidic enrichment at downstream positions (Fig. S3) . Zoom (A, B): zoomed in view of P + 1 to P + 7 positions. Overrepresented residues are displayed above the x-axis, and underrepresented residues are below the x-axis. The n(fg) and n(bg) values at the bottom left of the pLogo indicate the number of aligned foreground and background sequences used to generate the image, respectively. The red horizontal bars correspond to P = 0.05 (corrected for multiple hypothesis testing), and y-axis is logarithmic scale. The gray box indicates a 'fixed' residue. Additional pLogos for threonine-centered substrates are available in Fig. S3 . structure data. The processed ProPeL experimental data are provided in Table S2 . Interested readers may follow the detailed instructions for recreating these pLogos to dynamically explore the correlated positions within the motifs (see Supporting Information).
Using pLogos as a guide for substrate engineering and prediction
To corroborate the results from our ProPeL-derived pLogos, we conducted [c-32 P]ATP in vitro kinase assays by incubating recombinant PKA with custom peptide arrays. First, we evaluated whether the observed E. coli peptide substrates identified by ProPeL were suitable PKA substrates in vitro. Using our PKA WT pLogo and an internal version of the scan-x tool [23] , we scored the E. coli phosphopeptides identified in the PKA WT ProPeL experiments and selected two of the highest scoring peptides for synthesis (Observed Peptide 1 -PLRMRRGSIPALVNN, Observed Peptide 2 -IVLPRRLSDEVADRV). As a benchmark, we also selected a known human PKA WT substrate for synthesis (CDK16 S119 -EDINKRLSL-PADIRL [24] ). The in vitro kinase assay revealed that both the observed E. coli peptides and the human CDK16 S119 peptide were readily phosphorylated (Fig. 3A) , and a one-way ANOVA found that the means are not significantly different [F(2,14) = 0.56, P = 0.58349], verifying that phosphorylation sites obtained through ProPeL E. coli experiments are a suitable proxy for real human substrates.
Next, we validated the observed specificity drift of the PKA L205R mutation. We designed peptides based on the best residues at each position for each of the PKA WT and PKA L205R pLogos (RKRRRRKSFIENDRR and KRRRRRGSLDEDDQG, respectively) to assess the differential activity of each PKA variant for consensus substrates. While both peptides are viable substrates for both PKA variants, it is clear when comparing phosphorylation levels that the PKA WT pLogo-derived peptide is preferentially phosphorylated by PKA WT , while the PKA L205R pLogo-derived peptide is preferentially phosphorylated by PKA L205R (Fig. 3B,C) . This provides independent validation of the kinase specificity motifs identified by ProPeL using an orthogonal approach.
Having demonstrated that there is indeed a shift in substrate specificity, we sought to use this information to guide the design of peptide substrates with altered kinase selectivity. The gold-standard PKA consensus substrate Kemptide (LRRASLG) has been previously used to evaluate not only PKA WT activity but also PKA L205R activity [5] . As mentioned above, PKA WT displays a general preference for all hydrophobic residues in the P + 1 position, while PKA L205R retains only leucine from this hydrophobic grouping. As Kemptide contains arginine residues in the PÀ2 and PÀ3 positions and leucine at P + 1, it conforms to our specificity models for both PKA variants. We hypothesized that replacing the Kemptide P + 1 leucine with a valine (i.e., LRRASVG) would reduce phosphorylation by PKA L205R , while maintaining high phosphorylation levels by PKA WT . Indeed, our 'Kemptide +1V' peptide exhibits increased selectivity toward PKA WT over PKA L205R when compared with standard Kemptide (Fig. 3B,C) . Next, we investigated the biologically relevant regulatory subunit RIa interaction site (RRGAI). We hypothesized that by rationally mutating the RIa pseudo-substrate toward our model of PKA L205R specificity, we could 'rescue' the interaction between the Cushing's mutant kinase and the RIa-binding site. We synthesized an alanine-to-serine phosphoacceptor-substituted RIa peptide 'RIa (P 0 sub.)' to convert the interaction site to a potential substrate (KGRRRRGSISAEVYT). Based on our PKA L205R ProPeL experimental findings, we also synthesized a version of the peptide with the putative +1 and +2 residues mutated to aspartate and glutamate, respectively, yielding an 'RIa (acidic)' peptide (KGRRRRGSDEAEVYT). The in vitro kinase assays revealed that RIa (P 0 sub.) is phosphorylated at a higher level by PKA WT , and that RIa (acidic) is phosphorylated at a higher level by PKA L205R (Fig. 3B,C) . Finally, we wanted to test the feasibility of the hypothesis that the L205R mutation could induce substrate rewiring. Using the internal version of scan-x, we scored all of the known human PKA substrates (curated from the PhosphositePlus database [24] ) with the PKA WT and PKA L205R motifs, and determined CDK16 S119 as a candidate loss-of-function substrate for PKA L205R . The in vitro kinase assay revealed that phosphorylation of the CDK16 S119 peptide by PKA L205R was significantly reduced compared to PKA WT (Fig. 3D , n = 8 technical replicates, t-test, P = 3.04 9 10 À6 ). This result demonstrates both the feasibility of PKA L205R loss-of-function mutations, and that ProPeL-generated specificity models can be utilized for predicting kinase substrate rewiring.
Discussion
At present, disease-associated kinase mutations are largely classified as either inactivating or hyperactivating, and the potential impact of missense mutation on kinase specificity has not been fully explored [25, 26] . Although several groups have noted an increase in PKA L205R activity compared to wild-type, this activity has been assessed on only a small subset of known canonical PKA substrates (specifically CREB S133 , ATF1 S63 , Kemptide, and the PKA sensor AKAR4-NES) and in the presence of a regulatory subunit, typically RIa [4] [5] [6] [7] . Therefore, it is important to distinguish whether an increase in phosphorylation of downstream PKA targets results from an actual increase in intrinsic PKA L205R catalytic subunit activity, or is the result of constitutive PKA activity due to abolished regulatory subunit binding. Indeed, Lee et al. [27] recently demonstrated a reduction in isolated PKA L205R catalytic subunit activity, in agreement with our data (Fig. S2B,C) . Our results, combined with previous findings, suggest that we should report the specific relationship of kinase activity with respect to individual substrates, rather than just reporting the activity on arbitrary substrates (which may not be universal). For example, when using the canonical Kemptide substrate, there is a clear decrease in activity of specificity, and may explain why prior studies might have missed the altered specificity that we observe.
Altered PKA L205R specificity suggests the possibility that gain-of-function PKA signaling might extend beyond hyperphosphorylation of canonical substrates to include phosphorylation of novel PKA substrates, and the loss-of-function of individual substrates. While it is beyond the scope of this study to identify and validate PKA substrate rewiring in Cushing's syndrome, we demonstrated the feasibility of loss-of-function by showing that PKA L205R exhibits significantly reduced activity toward one PKA substrate, CDK16 S119 , and gain-of-function with increased activity toward noncanonical peptide substrates. Therefore, while the model that PKA L205R exhibits constitutive activity due to abolished regulatory subunit binding remains convincing, it is possible that the L205R mutation has additional effects resulting from an alteration in PKA's pool of target substrates.
In this study, we have demonstrated that the Cushing's syndrome PKA L205R mutation exhibits altered PKA substrate specificity. Using [c-32 P]ATP in vitro kinase assays, we validated this specificity change, utilized our experimentally determined kinase motifs to engineer PKA variant-selective substrates, and demonstrated the feasibility of PKA L205R loss-of-function. Together, our results suggest that the L205R mutation may influence Cushing's syndrome disease progression beyond simple hyperactivation of canonical PKA signaling, and demonstrate a powerful approach for investigating kinase substrate rewiring in human disease.
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